Saltar al contenido
Merck
  • Comparison of the physiological relevance of systemic vs. portal insulin delivery to evaluate whole body glucose flux during an insulin clamp.

Comparison of the physiological relevance of systemic vs. portal insulin delivery to evaluate whole body glucose flux during an insulin clamp.

American journal of physiology. Endocrinology and metabolism (2014-12-18)
Tiffany D Farmer, Erin C Jenkins, Tracy P O'Brien, Gregory A McCoy, Allison E Havlik, Erik R Nass, Wendell E Nicholson, Richard L Printz, Masakazu Shiota
RESUMEN

To understand the underlying pathology of metabolic diseases, such as diabetes, an accurate determination of whole body glucose flux needs to be made by a method that maintains key physiological features. One such feature is a positive differential in insulin concentration between the portal venous and systemic arterial circulation (P/S-IG). P/S-IG during the determination of the relative contribution of liver and extra-liver tissues/organs to whole body glucose flux during an insulin clamp with either systemic (SID) or portal (PID) insulin delivery was examined with insulin infusion rates of 1, 2, and 5 mU·kg(-1)·min(-1) under either euglycemic or hyperglycemic conditions in 6-h-fasted conscious normal rats. A P/S-IG was initially determined with endogenous insulin secretion to exist with a value of 2.07. During an insulin clamp, while inhibiting endogenous insulin secretion by somatostatin, P/S-IG remained at 2.2 with PID, whereas, P/S-IG disappeared completely with SID, which exhibited higher arterial and lower portal insulin levels compared with PID. Consequently, glucose disappearance rates and muscle glycogen synthetic rates were higher, but suppression of endogenous glucose production and liver glycogen synthetic rates were lower with SID compared with PID. When the insulin clamp was performed with SID at 2 and 5 mU·kg(-1)·min(-1) without managing endogenous insulin secretion under euglycemic but not hyperglycemic conditions, endogenous insulin secretion was completely suppressed with SID, and the P/S-IG disappeared. Thus, compared with PID, an insulin clamp with SID underestimates the contribution of liver in response to insulin to whole body glucose flux.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
D-(+)-Glucosa, ≥99.5% (GC)
Sigma-Aldrich
D-(+)-Glucosa, powder, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99.5%
Sigma-Aldrich
Dextrosa, 97.5-102.0% anhydrous basis, meets EP, BP, JP, USP testing specifications
Sigma-Aldrich
D-(+)-Glucosa, ≥99.5% (GC), BioXtra
USP
D-(+)-Glucosa, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
D-(+)-Glucosa, BioUltra, anhydrous, ≥99.5% (sum of enantiomers, HPLC)
Sigma-Aldrich
Glucagon, synthetic, powder, suitable for cell culture
Supelco
D-(+)-Glucosa, analytical standard
Sigma-Aldrich
D-(+)-Glucosa, ACS reagent
Sigma-Aldrich
D-(+)-Glucosa, suitable for mouse embryo cell culture, ≥99.5% (GC)
Supelco
D-(+)-Glucosa, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
D-(+)-Glucosa, Hybri-Max, powder, BioReagent, suitable for hybridoma
Sigma-Aldrich
Glucagon, ≥95% (HPLC), powder, synthetic
Sigma-Aldrich
D-(+)-Glucosa, 99.9 atom % 16O, 99.9 atom % 12C
Sigma-Aldrich
D-(+)-Glucosa, tested according to Ph. Eur.